New production facility for the large scale manufacturing of polymeric HPLC media confirms commitment to the purification of biopharmaceuticals
For the purification of synthetic peptides, oligonucleotides, and recombinant proteins, Polymer Laboratories has opened a new production facility for the large scale manufacture of polymeric HPLC media.
The addition of a new, state of the art manufacturing plant allows PL to produce high performance, reversed phase, PLRP-S 100Å and 300Å media in single lot sizes of up to 200kg, equivalent to 600L of packed column volume.
PLRP-S media is manufactured in particle sizes from 10µm to 20µm for use in axial compression process columns.
Increased production capacity ensures a reliable supply of quality media to meet customers' growing needs and to pack the largest of high performance process columns from a single media batch.
To ensure reproducible and consistent product quality, PL's prep/process media for peptide, oligonucleotide and protein purification is manufactured according to a Type II Drug Master File (DMF).
A Regulatory Support File (RSF) is available to provide comprehensive supporting documentation, including instruction sheets for handling, packing and cleaning in place with 1M NaOH.
The increased production capacity and product process documentation confirm PL's commitment to the provision of high performance polymeric materials for use in the purification of biopharmaceuticals.
